The present meta-analysis includes the most recent published large RCTs (SCORED, SOLOIST-WHF and EMPEROR-P), thus providing the most contemporary assessment of the total available evidence for SGLT-2 inhibitor therapy and cardiorenal outcomes in patients with or without T2D. Here, SLC5A2 is linked to type 2 diabetes mellitus.